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Protein-tyrosine phosphatases (PTPs), along with
protein-tyrosine kinases, play key roles in cellular
signaling. All Class I PTPs contain an essential active
site cysteinyl residue, which executes a nucleophilic
attack on substrate phosphotyrosyl residues. The
high reactivity of the catalytic cysteine also predis-
poses PTPs to oxidation by reactive oxygen species,
such as H2O2. Reversible PTP oxidation is emerging
as an important cellular regulatory mechanism and
might contribute to diseases such as cancer. We ex-
ploited these unique features of PTP enzymology to
develop proteomic methods, broadly applicable to
cell and tissue samples, that enable the comprehen-
sive identification and quantification of expressed
classical PTPs (PTPome) and the oxidized subset
of the PTPome (oxPTPome). We find that mouse
and human cells and tissues, including cancer cells,
display distinctive PTPomes and oxPTPomes,
revealing additional levels of complexity in the regu-
lation of protein-tyrosine phosphorylation in normal
and malignant cells.
INTRODUCTION
The phosphorylation of proteins on tyrosyl residues is controlled
by protein-tyrosine kinases (PTKs) (Lemmon and Schlessinger,
2010) and protein-tyrosine phosphatases (PTPs) (Alonso et al.,
2004), which direct diverse cellular processes, such as cell
growth, proliferation, and migration (Tonks, 2006). Aberrations
in PTKs or PTPs contribute to several human diseases, including
cancer (Julien et al., 2011; Lahiry et al., 2010). A systems level
understanding of cell signaling requires methods to identify
PTKs and PTPs, determine their expression levels, and monitor826 Cell 146, 826–840, September 2, 2011 ª2011 Elsevier Inc.their regulation. Most activated PTKs are phosphorylated on
tyrosine and can be identified by phosphotyrosine (pY)-proteo-
mics (Rikova et al., 2007; Zhang et al., 2005). By contrast, pro-
teomic approaches to assess PTP expression and regulation
have lagged behind.
The PTP superfamily comprises 107 genes, divided into four
families (Alonso et al., 2004). The largest, the class I cysteine-
based PTPs, can be subdivided into classical and dual-speci-
ficity PTPs (DUSPs). The classical PTP subfamily consists of
21 receptor and 17 nonreceptor PTPs that exclusively hydrolyze
pY residues. Classical PTPs contain a conserved ‘‘signature
motif,’’ [I/V]HCSXGXGR[S/T]G, within their active sites, wherein
the invariant cysteine is essential for catalysis (Andersen et al.,
2001). Owing to its low pKa (4.5–5.5), the catalytic cysteine exists
in the thiolate (S-) state at physiological pH (Zhang et al., 1994).
This property facilitates nucleophilic attack on substrate phos-
photyrosines (Denu and Dixon, 1998), but also renders PTPs
highly susceptible to oxidation by reactive oxygen species
(ROS) (Salmeen and Barford, 2005; Tanner et al., 2010).
Although high levels of ROS damage cellular components,
ROS, particularly H2O2, also function as intracellular second
messengers [reviewed in (den Hertog et al., 2005; Rhee et al.,
2000; Tonks, 2005)]. Early work showed that receptor tyrosine
kinase (RTK) activation leads to transient H2O2 production,
which is required for full RTK phosphorylation and downstream
signaling (Sundaresan et al., 1995). PTPs were proposed as
important ROS targets (Finkel, 1998), and soon PTPN1
(PTP1B) was found to be reversibly oxidized and inactivated in
response to EGFR activation (Lee et al., 1998). Subsequently,
studies have reported that oxidation of specific PTPs, including
PTPN11 (SHP2) in PDGF signaling (Meng et al., 2002), PTPN1
and PTPN2 (TC-PTP) in insulin signaling (Meng et al., 2004),
and PTPN6 (SHP1) in B cell receptor signaling (Singh et al.,
2005), is required for optimal responses to various stimuli.
Cancer cells often produce high levels of ROS (for review, see
Cairns et al., 2011; Liou and Storz, 2010), which could decrease
basal PTP activity and enhance tyrosyl phosphorylation (Ostman
et al., 2006). Indeed, total PTP activity is decreased in BCR/ABL
(Sattler et al., 2000) and Src (Gianni et al., 2008) transformed
cells and can be restored by antioxidants or PTK inhibitors.
Furthermore, overexpression of the ROS-producing protein
Nox1 can cause cellular transformation and tumor formation
(Arnold et al., 2001), implicating excess ROS production in
carcinogenesis.
The identification of ROS-inactivated PTPs might provide
important clues to key PTPs that regulate normal and oncogenic
signaling pathways. Yet while approaches to identify specific
oxidizedPTPsareavailable, it hasbeendifficult todevelopgeneral
methods that detect and quantify any reversibly oxidized PTP in
different physiological and pathological contexts. A modified in-
gel phosphatase assay is currently the best global assay for PTP
oxidation (Meng et al., 2002), but this approach is biased toward
nonreceptorPTPs (BurridgeandNelson, 1995), is notquantitative,
and requires the oxidizedPTP(s) to be identifiedby immunodeple-
tion.Weexploited the biochemistry of PTPcatalysis andoxidation
and an available monoclonal antibody against ‘‘hyperoxidized’’
PTP active sites to develop global quantitative proteomic ap-
proaches that monitor classical PTP expression and oxidation.
RESULTS
Design of qPTPome and q-oxPTPome Assays
H2O2 promotes reversible oxidation of PTPs to the sulfenic acid
(PTP-SOH) state (Rhee et al., 2000), which is labile and, in
different family members, rapidly rearranges to form a sulfenyla-
mide with the adjacent main-chain nitrogen (Salmeen et al.,
2003; van Montfort et al., 2003) or a disulfide bond to a nearby
cysteine (Chen et al., 2009). The sulfenylamide and disulfide
states help limit ‘‘hyperoxidation’’ to the sulfinic (PTP-SO2H)
and sulfonic (PTP-SO3H) acid states, which are biologically irre-
versible (Tonks, 2005).
We exploited these biochemical properties to develop
methods for quantifying classical PTP expression (qPTPome)
and oxidation (q-oxPTPome), respectively (Figure 1A and Fig-
ure S1 available online). Both methods use a monoclonal anti-
body (oxPTP Ab) raised against the signature motif of PTPN1
oxidized to the sulfonic acid (VHCSO3HSAG) (Persson et al.,
2005) to isolate ‘‘hyperoxidized’’ PTPs (PTP-SO3H). This anti-
body has been used for immunoblotting of cell lysates and to
monitor oxidation of specific PTPs (Groen et al., 2005; Persson
et al., 2004; Weibrecht et al., 2007). Its precise reactivity had
not been defined, but because the signature motif is highly
conserved, we suspected (and found; see below) that the oxPTP
Ab would react with most, if not all, classical PTPs.
Basal or ligand-induced PTP oxidation results in two pools of
PTPs: oxidized (PTP-SOH; inactive) and reduced (PTP-S-;
active). For q-oxPTPome, active PTPs are alkylated with N-ethyl-
maleimide (NEM; PTP-S-NEM), rendering them resistant to
further modification, while oxidized PTPs remain unaffected (Fig-
ure 1A). Excess NEM is removed by gel filtration, and reversibly
oxidized PTPs are reduced with dithiothreitol (DTT). Following
a buffer exchange, the reduced PTPs (representing PTPs that
initially were reversibly oxidized), are oxidized to the sulfonic
acid (PTP-SO3H) using pervanadate (PV) (Huyer et al., 1997).
For qPTPome, alkylation is omitted, and cells are lysed in thepresence of DTT to reduce PTPs to the active (PTP-S-) state.
Then, PTPs are ‘‘hyperoxidized’’ to the SO3H state and detected
by immunoblotting with the oxPTP Ab or processed for mass
spectrometry (MS). For MS, PV-treated lysates are digested
with trypsin, and PTP-SO3H active site peptides are purified
with the oxPTP Ab and identified (‘‘discovery’’ proteomics) by
LC-MS/MS. Quantification can be achieved by various methods,
including labeling with stable isotopes and/or chemical tags (for
review, see Gstaiger and Aebersold, 2009; Walther and Mann,
2010; Yates et al., 2009) or, as follows, by selected reaction
monitoring (SRM, also known as multiple reaction monitoring
or MRM) (for review, see Elschenbroich and Kislinger, 2011).
qPTPome Reliably Identifies Classical PTPs
For qPTPome, NIH 3T3 cells were lysed in the presence of DTT,
followed by a buffer exchange and treatment with PV. Multiple
bands were detected in immunoblots with the oxPTP Ab in PV-
treated, compared with untreated, lysates (Figure 1B). Next,
native or denatured PV-treated lysates were immunoprecipi-
tated and immunoblotted with the oxPTP Ab (Figure 1C). Again,
new bands were detected in the PV-treated lysates (Figure 1C,
compare lanes 5 and 6). Denaturing the lysate prior to immuno-
precipitation increased recovery of oxidized PTPs (Figure 1C,
compare lanes 4 and 6), suggesting that the epitope for the
oxPTP Ab is not very accessible in the native PTP-SO3H confor-
mation. As expected, NEM treatment prior to reductionmarkedly
decreased oxPTP Ab-immunoreactive bands (Figure 1C, lanes 3
and 5). We also immunoblotted oxPTP and anti-Ptpn11 immuno-
precipitates from denatured lysates with anti-Ptpn11 antibodies.
Similar levels of Ptpn11 were recovered in each immunoprecip-
itate, suggesting that immunoprecipitation by the oxPTP Ab was
quantitative (Figure 1C, compare lanes 2 and 6).
To identify the PV-inducible species, cell extracts were di-
gested with trypsin, and peptides immunopurified with the
oxPTP Ab were analyzed by LC-MS/MS. These experiments
revealed active site PTP-SO3H peptides from 17 classical
PTPs (Figure 1D). Importantly, unlike the in-gel PTPase approach
(see Introduction), qPTPome detected the D1 and D2 domains
from several RPTPs (Ptpra, Ptpre, Ptprf, and Ptprs). Near-
complete overlap in PTP expression was observed in biological
replicates using NIH 3T3 cells (Figure 1E) and other cell lines and
tissues (see Figure S2A).
To determine the range of classical PTPs that could be
detected, we performed qPTPome on tissues from C57BL/6J
mice (Figure 2A Table S1, and Table S2), several human cell lines
(Figure 2B, and Table S1, and Table S2) and the rat basophilic
leukemia line RBL2H3 (Figure S2B, Table S1, and Table S2).
Nearly all classical PTPs (17/17 nonreceptor and 19/21 RPTPs)
were identified, and PTPs accounted for 70% of the Cys-
SO3H-containing proteins recovered in these experiments (Table
S1). Notably, members of other phosphatase families (e.g.,
DUSPs) were not detected, indicating that the oxPTP Ab is highly
specific for the classical PTP signature motif. Other recovered
peptides had sequence similarity to this motif (see below) or
were from abundant proteins (Table S1).
Each cell line and tissue had a unique PTP profile. For
example, PTPN1 and PTPN2 were expressed ubiquitously,
whereas PTPRC and PTPRD were present more selectively.Cell 146, 826–840, September 2, 2011 ª2011 Elsevier Inc. 827
Protein MW (kDa) Oxidized Active Site 
Ptpn1 50 Yes 
Ptpn2 47 Yes 
Ptpn3 104 Yes 
Ptpn4 106 Yes 
Ptpn6 68 Yes 
Ptpn9 68 Yes 
Ptpn11 68 Yes 
Ptpn12 87 Yes 
Ptpn13 270 Yes 
Ptpn14 135 Yes 
Ptpn21 133 Yes 
Ptpn23 185 Yes 
Ptpra 94 Yes (D1 & D2) 
Ptpre 83 Yes (D1 & D2) 
Ptprf 211 Yes (D1 & D2) 
Ptprk 165 Yes 
Ptprs 168 Yes (D1 & D2) 
B
A
C D
E
Figure 1. Development of qPTPome and q-oxPTPome
(A) Scheme for each assay.
(B) NIH 3T3 cells were lysed in presence of DTT, applied to a gel filtration column, treated with PV or left untreated, and then analyzed by immunoblotting with the
oxPTP Ab.
(C) Native and denatured PV-treated lysates from (B) were immunoprecipitated with oxPTP or Ptpn11 antibodies, as indicated, and analyzed by immunoblotting.
(D) PTPs in NIH 3T3 cells, as identified by qPTPome.
(E) Venn diagram demonstrating reproducibility of the qPTPome assay (n = 3). See Figure S1 for additional variations of these assays.There was near-complete overlap between PTPs identified by
qPTPome and in published microarray analyses (Figure 2C and
Table S1), providing further evidence of the reliability of our
assay. This correlation was not absolute, though, indicating828 Cell 146, 826–840, September 2, 2011 ª2011 Elsevier Inc.that posttranscriptional mechanisms contribute significantly to
determining PTP protein levels.
We also applied our method to a cell type with an unknown
PTP expression profile. Platelets are anuclear and express only
Figure 2. qPTPome Broadly Identifies Classical PTPs in Cell Lines and Tissues
(A and B) The indicated mouse (A) and human (B) cell lines and tissues were profiled by qPTPome. Classical PTPs identified are shown as black boxes.
(C) Comparison of qPTPome results (blue boxes) with published microarray data (black boxes). Correlations for each PTP were evaluated by Spearman
r coefficient, as represented by the black-red scale.
(D) PTPs in human platelets, as identified by qPTPome.
(E) Multiple sequence alignment showing sequence of tryptic fragments containing the catalytic cysteines of each classical PTP. PTPs identified by qPTPome are
bolded. Also, see Figure S2 and Tables S1 and S2.small amounts of residual megakaryocyte mRNA, making it
difficult to define their PTPome by RNA-based approaches.
Using qPTPome, we identified 16 PTPs in platelets (Figure 2D),including PTPN2, PTPRA, and PTPRE, which had not been
identified previously. When antibodies were available, these
identifications were confirmed by immunoblotting (Figure S2C).Cell 146, 826–840, September 2, 2011 ª2011 Elsevier Inc. 829
The above data set allowed us to define the specificity of the
oxPTP Ab. We aligned the sequences of the tryptic peptides
from the active sites of all classical PTPs, highlighting those de-
tected by qPTPome (Figure 2E and Figure S2D). Although the D1
domains of Ptprc, Ptprm, Ptprk, Ptprt, and Ptpru were identified,
their D2 domains, which cluster at the top of the multiple
sequence alignment, were not. The active site sequences of
these D2 domains (VHCRDG and [I/V]HCLNG) diverge substan-
tially from the sequence used to generate the oxPTP Ab. To ask if
the oxPTP Ab could recognize these sequences, we performed
immunoprecipitationswith synthetic PTP-SO3H peptides. As ex-
pected, the oxPTP Ab isolated the Ptpn1 peptide, but not the D2
domains of Ptprk, Ptprm, Ptprt, and Ptpru (data not shown).
These experiments suggested that the oxPTP Ab recognizes
[I/V]HCSO3HS[A/S]G, and that, given their divergent active sites,
Ptprn (VHCSDG) and Ptprn2 (VHCSDG) also would not be
detectable. Notably, Ptprn and Ptprn2 are catalytically inactive
(Gross et al., 2002); hence, qPTPome can identify all catalytically
active classical PTPs in a single MS experiment.
Quantification of the PTPome
Selected reaction monitoring (SRM) is a label-free method that
determines the relative abundance of peptide ions by measuring
signals associated with specifically defined, distinctive, coelut-
ing parent ion-to-product ion transitions (Picotti et al., 2009).
We developed a multiplexed SRM (mSRM) protocol to quantify
the classical PTPome or oxPTPome from human, mouse, or rat
(Figure S3A). Following enrichment by the oxPTP Ab, PTP
peptide ions and their product ion fragments first were observed
in ‘‘discovery mode’’ LC-MS/MS, and then SRM transitions for
each PTP were designed, optimized, and combined into a single
mSRM protocol (Table S3). The optimized mSRM transitions
were validated for several (50%)mouse and human PTPs using
synthetic peptides (Table S3). Furthermore, all active site
peptides from classical PTPs in NIH 3T3 (Figure S3B) and
A431 (Figure S3C) cells were immunodepleted by the oxPTP
Ab, demonstrating that the assay is quantitative.
Next, we assayed Ptpn11fl/KO fibroblasts (Figure 3A), in
which 4-hydroxytamoxifen (4-OHT) addition activates a Cre-ER
fusion protein and evokes deletion of a floxed Ptpn11 allele
(Ptpn11KO/KO). Notably, the Ptpn11 signal from 4-OHT-treated
cells was much lower than from controls, whereas their Ptpn1
signals were similar (Figure 3B). Moreover, the SRM signals
paralleled the respective Ptpn11 and Ptpn1 levels detected by
immunoblotting (Figure 3C). To display the mSRM signals for
all PTPs simultaneously, we developed a heat map representa-
tion (Figure 3D and Table S3), in which the relative abundance
of each PTP is shown in shades of red and the magnitude of
the SRM signal for each PTP (from control cells) is indicated by
shades of blue (black denotes no signal/undetectable expres-
sion). With the exception of Ptpn11, PTP expression was largely
unaffected by 4-OHT treatment.
To see if qPTPome could be used for tissues, we assayed
brains from Ptprd+/+, Ptprd+/, and Ptprd/ mice (Mizuno
et al., 1993). As expected, Ptprd levels, obtained by SRM of
the Ptprd D1 domain, were progressively lower in Ptprd+/+,
Ptprd+/, and Ptprd/ brains (Figure 3E); by contrast, Ptpn1 ex-
pression remained similar. These findings agreed with a global830 Cell 146, 826–840, September 2, 2011 ª2011 Elsevier Inc.immunoblot using the oxPTP Ab (Figure 3F) and with RT-PCR
measurements of Ptprd mRNA (Figure 3G). Also consistent
with the oxPTP immunoblot, there were no significant changes
in classical PTP expression aside from Ptprd in these samples
(Figure 3H and Table S3).
As implemented above, qPTPome displays the relative level of
each classical PTP. We asked if, by combining qPTPome with
absolute quantification (AQUA) (Gerber et al., 2003), the absolute
amount of a PTP could be determined (Figure S1). We synthe-
sized a Ptpn11-SO3H active site tryptic peptide containing a
‘‘heavy’’ arginine (six 13C and four 15N). Using a standard curve
generated with this peptide (Figure 3I), we found that our SRM
assay is linear over at least three orders of magnitude. By com-
paring the intensities of coeluting ‘‘heavy’’ (AQUA) and ‘‘light’’
(endogenous) Ptpn11-SO3H peaks recovered by the oxPTP Ab
(Figure 3J) and assuming complete digestion with trypsin, we
determined that there are 32,000 copies of Ptpn11 in each
NIH 3T3 cell. This measurement compares well (within 4-fold)
with immunoblot determinations (Figure S3D).
Quantification of the PTP ‘‘Redoxome’’
Next, we attempted to quantify PTP oxidation (Figure 4A). NIH
3T3 cells were stimulated with increasing concentrations of
H2O2 for 5 min and analyzed by q-oxPTPome. In parallel,
qPTPome measurements were obtained to assess the stoichi-
ometry of PTP oxidation. Under these conditions, the Ptpn6
and Ptpn11 SRM profiles showed dose-dependent, but differen-
tial increases in oxidation (Figure 4A), which were confirmed by
immunoblotting (Figure 4B). We used a heat map to display the
oxidized proportion of each PTP relative to its total amount
(q-oxPTPome/qPTPome; Figure 4C and Table S4). As expected,
under normal growth conditions, most PTPs had very low levels
of basal oxidation to the PTP-SOH or SO3H states. By contrast,
Ptpn23, Ptpra D2, Ptprf D2, and Ptprk D1 had high basal oxida-
tion. With the exception of Ptprk D1, these PTP domains report-
edly are catalytically inactive (Gingras et al., 2009; Persson et al.,
2004). The D1 and D2 domains of specific RPTPs showed clear
differences in oxidation sensitivity. For example, Ptpra D1 had
a low level of oxidation, while its D2 domain was highly oxidized.
By contrast, Ptprs D1 and D2 both showed low basal oxidation.
As expected, increasing the H2O2 concentration increased the
oxidation of multiple PTPs, including Ptpn1, Ptpn3, Ptpn9, and
Ptpra D1 (Figure 4C). Surprisingly, though, Ptpn23 and Ptpra
D2 oxidation appeared to decrease.
We suspected that this might reflect oxidation to the SO2H
state, which should not be converted to the SO3H state by PV
(Huyer et al., 1997) and hence would not be recognized by
SRM. To test this possibility, we modified the q-oxPTPome pro-
tocol (Figure 4D; see Experimental Procedures for details) to
enable identification and quantification of all PTP oxidation
states (S-, SOH, SO2H, SO3H). Not surprisingly, most PTPs
were oxidized by 10mMH2O2 (Figure 4E and Table S4). Yet while
several PTPs were converted to the SO2H state, including
Ptpn23 andPtpra D2, very fewwere converted to the SO3H state.
Hence, extremely high levels of oxidative stress are required to
completely oxidize PTPs inside cells. Most other PTPs, including
Ptpn11 and Ptprs D1, showed high levels of reversible oxidation
(PTP-SOH), whereas a few remained reduced.
BH
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Figure 3. PTP Quantification Using qPTPome
(A) Ptpn11fl/KO cells stably expressing CreER were treated with 4-OHT or left untreated, then assessed by qPTPome.
(B) Representative SRM profiles for Ptpn11 and Ptpn1. Quantification of each PTP is displayed next to its elution profile (***p < 0.002, paired Student’s t test; two
biological replicates, each with two technical replicates).
(C) Immunoblot showing PTP expression levels. Arrow shows position of Ptpn11.
(D) Heat map showing relative changes (compared with untreated cells) in PTP expression (measured by qPTPome) following 4-OHT treatment. The intensity
value is the average signal for the SRM profiles for each PTP in untreated cells.
(E) Ptprd+/+, Ptprd+/, and Ptprd/ brains were profiled by qPTPome (n = 3; three technical replicates each). Representative SRM profiles are shown for
Ptprd and Ptpn1, with quantification of each displayed next to the profiles. Data represent mean ±SEM (*p < 0.05; **p < 0.01; ***p < 0.001, ANOVAwith Bonferroni
post-test).
(F) Immunoblot with oxPTP Ab showing PTP expression in Ptprd mutant brains. Arrow shows position of Ptprd.
(G) Ptprd mRNA levels (assessed by qPCR; n = 3). Data represent mean ± SEM (***p < 0.001, ANOVA with Bonferroni post-test).
(H) Relative levels of PTP expression (measured by qPTPome) in Ptprd mutant (compared with Ptprd+/+) brains.
(I) Standard curve of MS peak area for Ptpn11 AQUA peptide (n = 3).
(J) SRM peak of the AQUA peptide mixed with native Ptpn11 peptide from NIH 3T3 cells. Also, see Figure S3 and Table S3.
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Figure 4. Monitoring Multiple PTP Oxidation States by q-oxPTPome
(A) Experimental scheme (left). NIH 3T3 cells were stimulated with the indicated concentrations of H2O2 for 5 min and analyzed by q-oxPTPome (n = 2; four
technical replicates each). Representative SRM profiles for Ptpn6 and Ptpn11 (right).
(B) Detection of Ptpn6 and Ptpn11 oxidation. Following H2O2 stimulation, cells were processed by q-oxPTPome, immunoprecipitated with Ptpn6 or Ptpn11
antibodies and analyzed by immunoblotting, as indicated.
832 Cell 146, 826–840, September 2, 2011 ª2011 Elsevier Inc.
We next assessed the changes in PTP oxidation caused by
exposure of NIH 3T3 cells to buthionine sulphoximine (BSO),
which inhibits glutathione synthesis. As expected, intracellular
ROS levels increased (Figure 4F), and concomitantly, several
PTPs showed increased oxidation (Figure 4G and Table S4).
Interestingly, although PTP oxidation levels were similar in BSO-
treated and H2O2 (1 mM)-stimulated cells, the profile of oxidized
PTPs differed significantly (compare Figures 4C and 4G).
Quantifying PTP Nitrosylation
PTPs also can be regulated by reversible nitrosylation of their
active site cysteines. Targeted indirect approaches have been
used to detect nitrosylation of a few PTPs, including PTPN1
and PTPN11 (Li and Whorton, 2003). To see if our method could
monitor PTP nitrosylation, NIH 3T3 cells were exposed to three
different nitrosylating agents, processed and analyzed by
q-oxPTPome. We detected nitrosylation of several PTPs (Fig-
ure 4H and Table S4), including Ptpn1 and Ptpn11 (Hsu and
Meng, 2010; Li andWhorton, 2003). Consistent with the q-oxPT-
Pome signals arising from nitrosylation, not oxidation, SRM
signals for Ptpn23 and Ptpra D2 did not decrease (Figure 4H),
and ROS levels remained unchanged (data not shown) in cells
exposed to these agents.
Application of qPTPome and q-oxPTPome
to Cancer Cells
ROS levels often increase in cancer (Liou and Storz, 2010).
Although increased oxidation of individual PTPs has been re-
ported in selected cancer cell lines (Lou et al., 2008), the global
effects of excess ROS on PTP oxidation have not been as-
sessed. As a proof of principle, we analyzed A431 (Figure 5A
and Table S5) and NIH 3T3 cells transformed with constitutively
active Src (Src Y527F; Figure 5B and Table S5). Many PTPs were
reversibly oxidized in both lines, with generally higher levels of
oxidation in A431 cells. Notably, we detected 20% oxidation
of PTPN1 in A431 cells, remarkably similar to the 25% oxidation
determined using a targeted MS method (Lou et al., 2008).
We compared PTP oxidation in A431 and Src Y527F cells with
that in cell lines derived from several types of cancer (Figures 5C
and 5D and Table S5). Global PTP oxidation was higher in Src
Y527F cells, compared with nontransformed NIH 3T3 cells.
A431 and H1975 cells showed the highest levels of PTP oxida-
tion and the highest levels of intracellular ROS (Figures S4B
and S4C). Some PTP domains (e.g., PTPRA D2, PTPN23) were
highly oxidized in all cancer cells tested; others (e.g., PTPN1,
PTPN11) had lower and variable levels of basal oxidation in these
cell lines.(C) Heat map displaying levels of PTP oxidation following H2O2 stimulation, mea
boxes denote high levels. The intensity value is the average signal for the SRM p
(D) Scheme showing modifications of qPTPome and q-oxPTPome to assess all p
asterisk indicates a buffer exchange.
(E) Fraction of each PTP in each potential oxidation state (i.e., S-, SOH, SO2H, S
(F) ROS levels in NIH 3T3 cells treated with 100 mM BSO (n = 6 ***p < 0.001, Stu
(G) Levels of PTP oxidation in cells treated with 100 mM BSO or left untreated (
oxidation following BSO treatment.
(H) Levels of nitrosylation measured by q-oxPTPome following stimulation with
socysteine (CSNO). Asterisks indicate PTPs that were nitrosylated. See also TabWe then compared PTP oxidation in six HER2+ breast cancer
cell lines. Although some PTPs were differentially oxidized
(Figures 5E and 5F and Table S5), there was less heterogeneity
between these lines than between lines derived from different
types of cancer (compare Figures 5C and 5E). Also, while there
were somegeneral trends in relativeoxidation levels, eachcancer
linecontainedauniqueprofileof oxidizedPTPs.Notably, theROS
levels in a given cell line and the extent of PTP oxidation did not
correlate strongly (compare Figure 5 and Figures S4B and S4D).
To ask if PTP oxidation was controlled by a mutant PTK, we
treated SrcY527F cells with the Src kinase inhibitor, PP2. Global
tyrosyl phosphorylation (Figure 6A) and ROS (Figure 6B) levels
decreased following PP2 treatment, accompanied by an overall
decrease in PTP oxidation (Figure 6C and Table S6). Neverthe-
less, some PTPs, (e.g., Ptpn3 and Ptpra D2) remained oxidized
following PP2 treatment.
Combining qPTPome with Phosphotyrosine Proteomics
to Suggest PTP Substrates
Finally, we asked if combining qPTPome with pY-proteomics
could suggest PTP/substrate relationships. We used qPTPome
to quantify PTP expression in several multiple myeloma (MM)
cell lines (Figure 7A and Table S7) and measured 93 unique
pY sites in the same cells by pY-proteomics (Figure 7B and
Table S7). Using partial least-squares regression (PLSR) anal-
ysis, we sought relationships between the levels of various
pY-peptides and the expression of specific PTPs (see Experi-
mental Procedures for details). The resultant model predicted
relative pY-peptide levels well (Figure 7C and Table S7), with
Component 1 accounting for 97% of the variance and Compo-
nent 2 explaining another 2%. PTPN1 levels correlated most
strongly with Component 1, with PTPN6 and PTPN11 also
contributing significantly. PTPN7 explained most of the variation
in Component 2, and contributed to Component 1.
Overall, PTPN1, PTPN6, PTPN7, and PTPN11 levels could
explain the majority of the variation for many of the pY sites ana-
lyzed. Interestingly, the site best explained by the first two
components was from TYK2 (Table S7), a known PTP1B sub-
strate (Myers et al., 2001). The relative pY levels of the FGFR3
activation loop phosphotyrosyl residue also were highly corre-
lated with Components 1 and 2 (Table S7). Surprisingly, these
correlations were positive: peptide phosphorylation increased
as the PTP expression level increased (Table S7). Nevertheless,
given the prominent role of PTPN1 in regulating tyrosyl phos-
phorylation of several other RTKs (Bourdeau et al., 2005), we
tested the effects of a PTPN1 shRNA on one of these lines
(KMS11). Remarkably, PTPN1 depletion led to increased tyrosylsured by q-oxPTPome. A black box indicates low levels of PTP oxidation; red
rofiles for each PTP measured by qPTPome.
otential PTP oxidation states (n = 2; each with three technical replicates); the
O3H) following 10 mM H2O2 stimulation.
dent’s t test). Data represent mean ± SEM.
n = 2; two technical replicates each). Asterisks indicate PTPs with increased
S-nitroso-N-penicillamine (SNAP), S-nitrosoglutathione (GSNO), or S-nitro-
le S4.
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Figure 5. Cancer Cells Have Unique PTP Oxidation Profiles
(A and B) Heat map showing basal PTP oxidation in A431 (A) and Src Y527F-transformed NIH 3T3 (B) cells, measured by q-oxPTPome (n = 2; two technical
replicates each). ‘‘Negative control’’ represents cells that were lysed in the presence of DTT, treated with NEM followed by PV, and analyzed by LC-MS/SRM.
(C) Basal PTP oxidation in cancer lines determined by q-oxPTPome (n = 2; two technical replicates each).
(D) Same as (C), but with scale altered to show PTPs that were oxidized to lower extents.
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Figure 6. Reversibility of PTP Oxidation in Cancer Cells following Oncogene Inhibition
(A and B) (A) Antiphosphotyrosine immunoblot and (B) ROS levels of untransformed and Src Y527F cells treated with or without PP2, respectively. Data represent
mean ± SEM (n = 3; ***p < 0.001, ANOVA with Bonferroni post-test).
(C) Heat map showing effects of PP2 on levels of PTP oxidation in Src Y527F cells (n = 2; two technical replicates each). Asterisks indicate PTPs with decreased
oxidation following PP2 treatment. See also Table S6.phosphorylation of FGFR3 and several other proteins, including
one with the molecular weight of TYK2 (Figure 7D). These data
suggest that, like TYK2, FGFR3 is probably a bona fide in vivo
target of PTPN1.
DISCUSSION
By using proteomic methods that enable comprehensive anal-
ysis of the classical PTPome (Figure 1A), we identified the
PTPs in multiple human, mouse, and rat cell lines and tissues
(Figure 2), including platelets (Figure 2D), cells in which RNA-
based approaches have been of limited benefit. Our studies
uncover significant posttranslational regulation of PTP levels
(Figure 2C) and unanticipated complexity in PTP oxidation
evoked by exogenous and endogenous ROS in normal and
neoplastic cells (Figures 4–6). Such differential PTP oxidation
represents a new layer of complexity in signal transduction.
Furthermore, combining our assay with pY-proteomics can
help to identify PTP substrates (Figure 7).
We used SRM to quantify PTP expression because it is easily
applied to tissues andcell lines, but our assayalsoaccommodates
other quantification methods (Yates et al., 2009). Additional varia-
tions could permit simultaneous identification of posttranslational
modifications (Figure S1): e.g., the oxPTP Ab could be used to
isolate full-length (denatured) PTPs, and phosphorylated tryptic
peptides could be recovered (with TiO2 or anti-pY antibodies), fol-
lowed byMS. The oxPTP Ab does not detect DUSPs, but by using
more degenerate anti-Cys-SO3H hapten antibodies, analogous(E) Basal PTP oxidation in HER2+ breast cancer lines measured by q-oxPTPome
(F) Same as (E), but with scale altered to show PTPs that were oxidized to lowerapproaches could monitor oxidation (and expression) of these
(and other) cysteinyl proteins (Figure S1).
The lack of global methods to identify oxidized PTPs has
hampered progress on redox regulation. Several other indirect
approaches use an overall strategy similar to q-oxPTPome.
The modified in-gel PTPase assay (Meng et al., 2002) has been
the most successful, but it relies on immunodepletion for PTP
identification, rarely detects RPTPs and is not quantitative. The
modified cysteinyl-labeling assay isolates oxidized PTPs using
iodoacetylpolyethylene oxide biotin (IAP-Biotin) (Boivin et al.,
2010) or activity-based probes, such as a-bromobenzylphosph-
onate biotin (BBP-Biotin) (Kumar et al., 2004). Direct approaches
using dimedone, which reacts selectively with SOH groups,
represent a promising alternative (Poole and Nelson, 2008).
Biotin-coupled dimedone probes (Nelson et al., 2010) and dime-
done-specific antibodies (Seo and Carroll, 2009) are available.
However, none of these approaches have been developed
into a global MS assay for PTP oxidation. Recently, a modified
IAP-Biotin probe was used to identify reactive cysteinyl residues
by MS (Weerapana et al., 2010), but only three PTP-derived
peptides were detected (from >1000 cysteine-containing
species), and none corresponded to active site peptides. The
high reactivity of IAP-Biotin with any reactive S- probably in-
creases the background of abundant (non-PTP) proteins, which
also could be problematic for dimedone-based approaches.
These limitations are surmounted by q-oxPTPome, which uses
a highly specific antibody to purify PTPs. Notably, q-oxPTPome
cannot yet identify the PTPs oxidized upon growth factor(n = 2; two technical replicates each).
extents. Also, see Figure S4 and Table S5.
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Figure 7. Combining qPTPome and Phosphotyrosine Proteomics
(A) Heat map showing relative PTP expression (based on z-score across all lines) measured by qPTPome in a panel ofMMcell lines (n = 2, two technical replicates
each). Black box indicates PTPs that were not identified in any line.
(B) Relative phosphotyrosine peptide levels (based on z-score across all MM lines) in the same cells (n = 2).
(C) Correlation loadings plot displaying results of the PLSR analysis.
(D) Lysates from KMS11 cells stably infected with scrambled or PTPN1 shRNAs were immunoprecipitated with FGFR3 antibodies and immunoblotted with
antiphosphotyrosine or -FGFR3 antibodies (top). Immunoblots of total cell lystate (TCL) with the indicated antibodies (bottom). See also Table S7.
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stimulation, probably because only a small subset of PTPs is in-
activated (under steady state conditions) by growth factor-
evoked ROS (e.g., see den Hertog et al., 2005; Rhee et al.,
2000;Woo et al., 2010). Similar obstacles confronted initial phos-
phoproteomic (including pY-proteomic) methods, prior to
secondary enrichment strategies (Ahn et al., 2007; Pandey
et al., 2002).
Our results add to growing evidence that ROS production and
PTP oxidation are highly controlled in cells (Li et al., 2006; Woo
et al., 2010). First, because our assay is quantitative, we can
provide an upper bound on growth factor-induced increases in
PTP oxidation (<5%). For such a small change to impact
signaling (see Introduction), local control would be essential.
Consistent with in vitro studies (Groen et al., 2005; Weibrecht
et al., 2007), we find that PTPs also differ in relative oxidation
sensitivity in cells. Surprisingly, though, the pattern of oxidized
PTPs in cells stimulated by exogenous H2O2 differs from that
evoked by increasing endogenous H2O2 levels (Figure 4).
Furthermore, different cancer cells have distinct PTP oxidation
profiles (Figure 5) that do not simply correlate with global ROS
levels (Figure S4), again consistent with the idea that local ROS
alterations are critical for altering tyrosyl phosphorylation events.
Interestingly, transformation can have fairly durable effects on
redox homeostasis, as oxidation of some PTPs cannot be
reversed readily by oncogene inhibition (Figure 6). Further anal-
yses of this phenomenon might shed light on key regulators of
local ROS production/redox regulation.
Finally, qPTPome can be combined with pY-proteomics to
suggest specific PTP substrates (Figure 7). We identified four
PTPs that appeared to play a key role in regulating phosphotyro-
syl protein homeostasis in MM cells. Two of these PTPs have
been implicated inMM: PTPN6 is reportedly a tumor suppressor,
whereas PTPN7 is overexpressed (Julien et al., 2011). PTPN11 is
a known positive regulator of the RAS-MAPK pathway and is a
bona fide oncogene (Chan et al., 2008). Although PTPN11 has
not been implicated specifically inMM, it is required for the trans-
formation of NIH 3T3 cells expressing oncogenic FGFR3 (Agazie
et al., 2003), a commonMMoncogene. Moreover, PTPN1 deple-
tion in KMS11 cells leads to FGFR3 hyperphosphorylation and
increased global phosphotyrosine levels (Figure 7D), suggesting
that PTPN1 may be a key negative regulator of FGFR3. Unex-
pectedly, expression of PTPN1 (and the other three PTPs) corre-
lates positively with tyrosyl phosphorylation of several peptides,
yet knockdown causes increased phosphorylation of the same
species. Conceivably, these apparently paradoxical findings
reflect an attempt by MM cells to limit the effects of excess
FGFR3 signaling by upregulating its negative regulators.
In any case, our results argue strongly that altered redox regu-
lation provides an additional level of complexity to the cancer
phenotype. Further refinement and application of qPTPome
and q-oxPTPome should help delineate the contribution of
ROS regulation of PTPs to normal and pathological cell signaling.EXPERIMENTAL PROCEDURES
Cells and Viral Infection
Cell lines were cultured under standard conditions and treated with H2O2
(Bioshop) for 5min or 100 mMBSO (Sigma) for 24 hr, as indicated. Nitrosylationwas induced by exposing cells for 30 min to 0.5 mM SNAP (Calbiochem) and
L-cysteine (Sigma), GSNO (Alexis Biochemicals) and L-cysteine or CSNO
(Sigma), each prepared as described (Li and Whorton, 2003). Src Y527F cells
were provided by Dr. S. Courtneidge (Sanford-Burnham Medical Research
Institute, USA) and treated with 10 mM PP2 (Calbiochem) for 4 hr, when indi-
cated. Generation of Ptpn11fl/KO cells and deletion of the floxed Ptpn11 allele
are described in Supplemental Information. Lentiviruses expressing PTPN1
shRNA or a nonsilencing control hairpin were generated by standard proce-
dures and used to infect KMS11 cells. Human platelets were prepared by stan-
dard techniques (Pearce et al., 2004). For further details, see Supplemental
Information.
Immunoblotting
Lysates were prepared in RIPA buffer containing a protease and phosphatase
inhibitor cocktail, clarified, resolved by SDS-PAGE and analyzed by immuno-
blotting. For details, see Supplemental Information.
Quantitative Real-Time PCR
RNA from brains of 10-week-old Ptprd+/+, Ptprd+/, and Ptprd/ mice
(C57BL/6J) was reverse transcribed and analyzed by Sybr green-based
qPCR (Sigma), according to the manufacturer’s instructions. For details, see
Supplemental Information.
ROS Levels
Cells (80% confluence) were serum-starved overnight and treated as
indicated. Plates were washed with PBS (23), trypsinized, incubated for
5 min with 300 nM DCF-DA (Invitrogen) at 37C and washed immediately
with ice-cold PBS (33). Mean fluorescence intensity (MFI) was quantified by
flow cytometry (FACs Calibur).
qPTPome
Cells or tissues were homogenized in 50 mM HEPES (pH 7.4), 150 mM NaCl,
10% glycerol, 1% NP40, containing 10 mMDTT and a protease and phospha-
tase inhibitor cocktail. Lysates were clarified at 16,100 3 g for 15 min at 4C.
Supernatants were rotated in the dark at room temperature (RT) for 30 min.,
desalted by gel filtration into 20 mM HEPES (pH 7.4), treated with 100 mM PV
(Huyer et al., 1997), and rotated at 4C for 1 hr in the dark. Proteins were dena-
tured in SDS (0.5%) andEDTA (5mM) at 95C for 5min, diluted 5-fold intoNP40
buffer (20mMTris-HCl [pH 8.0], 137mMNaCl, 10%glycerol, 1%NP-40, 2mM
EDTA) and immunoprecipitated overnight at 4C with the oxPTP Ab (mouse
monoclonal anti-oxidized PTP active site antibody, clone 335636 [R&D
Systems]; 5 mgAb/mg protein) and 40 ml of packedproteinGSepharose beads.
For MS, samples were incubated in 9M urea/4.5 mMDTT at 60C for 30min,
cooled to RT, treated with 10 mM iodoacetamide (IAM) for 15 min in the dark,
diluted to a final concentration of 2 M urea, 20 mM HEPES (pH 8.0), and
digested overnight at RT in 10 mg/ml TPCK-trypsin (Pierce). IAM prevents
incomplete digestion due to disulfide bonds and ensures alkylation of other
cysteines (besides the catalytic cysteine) found in some PTP active site
peptides. Peptides were purified on a C18 column (Waters) by following the
manufacturer’s instructions, lyophilized, resuspended in 1.4 ml peptide IP
buffer (50 mM HEPES [pH 7.4], 50 mM NaCl) and incubated for 30 min on
a shaker at RT. Insoluble matter was removed by centrifugation at 2000 3 g.
Supernatants were collected, and PTP-SO3H active site peptides were
isolated by immunoprecipitation with the oxPTP Ab. Immunoprecipitates
were washed in 1 ml peptide IP buffer (33), followed by 1 ml HPLC grade
H2O (33), eluted by incubating with 80 ml 0.15% trifluoroacetic acid for
10 min at RT (33), dried, and analyzed by MS. The Ptpn11 AQUA peptide
(QESIVDAGPVVVHCSO3HSAGIGR; six
13C and four 15N) was purchased from
Thermo Scientific.
q-oxPTPome
q-oxPTPome buffer (50 mMHEPES [pH 6.5], 150 mMNaCl, 10% glycerol, 1%
NP40) was degassed overnight at 30–35 mmHg, transferred into a sealed
round-bottom flask equilibrated with N2, purged with N2 for 1 hr, transferred
to an anaerobic workstation (ESBE Invivo2 400), and treated with 10 mM
NEM (Sigma), 100 mg/ml catalase (Calbiochem) and a protease and phospha-
tase inhibitor cocktail. Cells were washed with ice-cold degassed PBS,Cell 146, 826–840, September 2, 2011 ª2011 Elsevier Inc. 837
transferred to the workstation and lysed in q-oxPTPome buffer. Lysates were
incubated for 1 hr at 4C in the dark, and homogenates were clarified at 16,100
3 g for 15 min at 4C. Supernatants were collected in the anaerobic worksta-
tion, and the buffer exchanged by gel filtration into degassed 20 mM HEPES
(pH 7.4). Desalted lysates were treated with 10 mM DTT and rotated in the
dark for 30 min at RT. After exchanging the buffer to remove DTT, samples
were treated with 100 mM PV, rotated at 4C for 1 hr in the dark and analyzed
by immunoprecipitation or MS. The DTT step is included to reduce all revers-
ibly oxidized PTPs; omitting this step prevents PV from accessing the PTP
active site and limits PTP oxidation to the SO3H state.
Measurement of all PTP Oxidation States
The total signal for each PTP is provided by qPTPome, while q-oxPTPome
determines the cumulative fraction of each PTP in the SOH and SO3H states.
To measure the proportion of each PTP in the SO3H state, H2O2-treated cells
were lysed in the presence of DTT and analyzed by SRM. The difference
between the q-oxPTPome and SO3H signal provides the fraction of PTPs in
the SOH state. Because the SO2H state is not converted to the SO3H state
by PV, the difference in signal between cells subjected to qPTPome in unsti-
mulated and H2O2-stimulated cells provides the fraction of each PTP in the
SO2H state. If PTPs are not converted to the SO2H state, the intensities from
these two procedures should be the same; any difference corresponds to
the fraction of each PTP converted to the SO2H state. Finally, the fraction of
active PTPs is the difference between the qPTPome and q-oxPTPome plus
SO2H signals, respectively (see Figure 4D).
LC-MS/MS
LC-MS, peptide identification, and SRM were performed by using standard
techniques and procedures. Samples were prepared for pY-proteomics as
described (St-Germain et al., 2009). See Supplemental Information for details.
Statistical Analysis
Data are presented as the mean ± SEM. Statistical significance was deter-
mined using Student’s t test (paired or unpaired) or one-way ANOVA, as
appropriate. If ANOVA was significant, individual differences were evaluated
using Bonferroni post-test. Statistical analyses were performed using Graph-
Pad Prism 5, with p < 0.05 considered significant.
Given the multivariate multiple linear regression problem: Y = XB+ε (1),
where X is an I x K predictor matrix of PTPs and Y is an I x J response matrix
of pY sites with both X and Y measured in five (I) different MM cell lines, PLSR
was implemented in the R (version 1.40) package PLS (Mevik and Wehrens,
2007) to fit a solution to (1) using the NIPALS algorithm. PLSR attempts to
predict Y from X and describe their common structure by simultaneously de-
composing the predictor and response variables into a common set of orthog-
onal factors and specific loadings: X = TPT; Y = UCT = TBCT, where T is the
score matrix, P is the loading matrix, B is a diagonal matrix of regression
weights, and C is a weight matrix. T and U are chosen such that their covari-
ance is maximal. ‘‘Leave-one-out’’ cross-validation was used to determine
the optimal number of components to use in the regression. Prior to fitting
the model, we excluded those PTPs and pY sites where there were two or
fewer measurements across the five cell lines.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
four figures, and seven tables and can be found with this article online at
doi:10.1016/j.cell.2011.07.020.
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